Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from ...

The Food and Drug Administration said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mo ...

Each participant received weekly doses of tirzepatide—either 5 mg, 10 mg, or 15 mg—for three years. At the end of this period, the results were impressive. On average, participants lost ...

Compared with semaglutide and insulin, tirzepatide was associated with improved glycemic control and weight loss outcomes among patients with type 2 diabetes. Tirzepatide is associated with longer ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes ...

A recent analysis of the SURPASS-3 trial unravels the impact of treatment with the drug tirzepatide on muscle volume and fat infiltration in individuals with type 2 diabetes. Published in The ...

Tirzepatide's uptake was rapid post-launch, surpassing other GLP-1 RAs and SGLT2 inhibitors, while conventional GLMs like metformin and insulin declined. The approval of tirzepatide for type 2 ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight or obesity who do not have diabetes, according to ...

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...

This post hoc analysis of the SURMOUNT-1 study, at 3 years, aimed to assess weight regain from nadir weight over 3 years (36 months / 176 weeks) with tirzepatide treatment. The original SURMOUNT-1 ...